ATX II, a sodium channel toxin, sensitizes skeletal muscle to halothane, caffeine, and ryanodine

Anesthesiology

Volumn 90, Issue 5, 1999, Pages 1294-1301

  Fletcher, Jeffrey E ^a,d   Adnet, Pascal J ^b   Reyford, Hugo ^b   Wieland, Steven J ^a   Stewart, Sherri L ^a   Rosenberg, Henry ^c  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b LILLE UNIVERSITY HOSPITAL   (France)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

^d Trinity Communications   (United States)

Author keywords

Gender; Muscle rigidity; Myotonia; Succinylcholine

Indexed keywords

CAFFEINE; HALOTHANE; RYANODINE; SEA ANEMONE TOXIN; SODIUM CHANNEL; SUXAMETHONIUM;

ARTICLE; DRUG SENSITIZATION; FORCE TRANSDUCER; HUMAN; HUMAN TISSUE; MALIGNANT HYPERTHERMIA; MEMBRANE DEPOLARIZATION; MUSCLE CONTRACTURE; MUSCLE RIGIDITY; MYOTONIA; NEUROMUSCULAR BLOCKING; PRIORITY JOURNAL; SEA ANEMONE; SKELETAL MUSCLE; SODIUM CURRENT;

ANIMALS; CAFFEINE; CNIDARIAN VENOMS; FEMALE; HALOTHANE; HUMANS; MALE; MALIGNANT HYPERTHERMIA; MUSCLE CONTRACTION; MUSCLE, SKELETAL; RATS; RATS, SPRAGUE-DAWLEY; RYANODINE; SODIUM CHANNELS;

EID: 0032964916     PISSN: 00033022     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000542-199905000-00012     Document Type: Article

References (51)

1. Rosenberg H: Clinical presentation of malignant hyperthermia. Br J Anaesth 1988; 60:268-73
2. Gronert GA: Malignant hyperthermia, Myology, 2nd Edition. Edited by Engel AG, Franzini-Armstrong C. New York, McGraw-Hill, 1994, pp 1661-78
3. Rosenberg H, Fletcher JE, Seitman D: Pharmacogenetics, Clinical Anesthesia, 3rd Edition. Edited by Banish PG, Cullen BF, Stocking RK. Philadelphia, Lippincott-Raven Publishers, 1996, pp 489-517
4. Nelson TE: Abnormality in calcium release from skeletal sarcoplasmic reticulum of pigs susceptible to malignant hyperthermia. J Clin Invest 1983; 72:862-70
5. Iaizzo PA, Klein W, Lehmann-Horn F: Fura-2 detected myoplasmic calcium and its correlation with contracture force in skeletal muscle from normal and malignant hyperthermia susceptible pigs. Pflugers Arch 1988; 411:648-53
6. 2+ regulation defects. Physiol Rev 1996; 76:537-92
7. MacLennan DH, Phillips MS: Malignant hyperthermia. Science 1992; 256:789-94
8. Levitt RC, Nouri N, Jedlicka AE, McKusick VA, Marks AR, Shutack JG, Fletcher JE, Rosenberg H, Meyers DA: Evidence for genetic heterogeneity in malignant hyperthermia susceptibility. Genomics 1991; 11:543-7
9. Deufel T, Golla A, Iles D, Meindl A, Meitinger T, Schindelhauer D, DeVries A, Pongratz D, MacLennan DH, Johnson KJ, Lehmann-Horn F: Evidence for genetic heterogeneity of malignant hyperthermia susceptibility. Am J Human Genet 1992; 50:1151-61
10. Robinson RL, Monnier N, Wolz W, Jung M, Reis A, Nuernberg G, Curran JL, Monsieurs K, Stieglitz P, Heytens L, Flicker R, van Broeckhoven C, Deufel T, Hopkins PM, Lunardi J, Mueller CR: A genome wide search for susceptibility loci in three European malignant hyperthermia pedigrees. Hum Mol Genet 1997; 6:953-61
11. Fletcher JE, Tripolitis L, Hubert M, Vita GM, Levitt RC, Rosenberg H: Genotype and phenotype relationships for mutations in the ryanodine receptor in patients referred for diagnosis of malignant hyperthermia. Br J Anaesth 1995; 75:307-10
12. Fletcher JE, Calvo PA, Rosenberg H: Phenotypes associated with malignant hyperthermia susceptibility in swine genotyped as homozygous or heterozygous for the ryanodine receptor mutation. Br J Anaesth 1993; 71:410-7
13. O'Flynn RP, Shutack JG, Rosenberg H, Fletcher JE: Masseter muscle rigidity and malignant hyperthermia susceptibility in pediatric patients. An update on management and diagnosis. ANESTHESIOLOGY 1994; 80:1228-33
14. Littleford JA, Patel LR, Bose D, Cameron CB., McKillop C: Masseter muscle spasm in children: Implications of continuing the triggering anesthetic. Anesth Analg 1991; 72:151-60
15. Van Der Speck AFL, Fang WB, Ashton-Miller JA, Stohler CS, Carlson DS, Schork MA: The effects of succinylcholine on mouth opening. ANESTHESIOLOGY 1987; 67:459-65
16. Russell SH, Hirsch NP: Anaesthesia and myotonia. Br J Anaesth 1994; 72:210-6
17. Paterson IS: Generalized rigidity following suxamethonium. A case report. Br J Anaesth 1962; 34:340-2
18. Morley JB, Lambert TF, Kakulas BA: A case of hyperpyrexia with myotonia congenita. Exerc Med Intl Congress Ser 1973; 295:543-6
19. Kallen RG, Cohen SA, Barchi RL: Structure, function and expression of voltage-dependent sodium channels. Mol Neurobiol 1994; 7:383-428
20. Barchi RL: Molecular pathology of the skeletal muscle sodium channel. Annu Rev Physiol 1995; 57:355-85
21. Cannon SC: Sodium channel defects in myotonia and and periodic paralysis. Ann Rev Neurosci 1996; 19:141-64
22. Lehmann-Horn F, Rüdel R: Molecular pathophysiology of voltage-gated ion channels. Reviews of Physiology, Biochemistry and Pharmacology. Edited by Blaustein MP, Grunicke H, Habermann E, Pette D, Schultz G, Schweiger M. Berlin, Springer, 1996, pp 195-268
23. Fletcher JE, Wieland SJ, Karan SM, Beech J, Rosenberg H: Sodium channel in human malignant hyperthermia. ANESTHESIOLOGY 1997; 86:1023-32
24. Redfern P, Lund H, Thesleff S: Tetrodotoxin resistant action potentials in denervated rat skeletal muscle. Eur J Pharmacol 1970; 11:263-5
25. Wieland SJ, Gong Q-H, Fletcher JE, Rosenberg H: Altered sodium current response to intracellular fatty acids in halothane-hypersensitive skeletal muscle. Am J Physiol 1996; 271:C347-53
26. Wieland SJ, Fletcher JE, Rosenberg H, Gong QH: Malignant hyperthermia: Slow sodium current in cultured human muscle cells. Am J Physiol 1989; 257:C759-65
27. Iaizzo PA, Lehmann-Horn F, Taylor SR, Gallant EM: Malignant hyperthermia: Effects of halothane on the surface membrane. Muscle Nerve 1989; 12:178-83
28. 1306-to-alanine mutation in the adult muscle sodium channel α-subunit gene. ANESTHESIOLOGY 1995; 82:1097-103
29. Moslehi R, Langlois S, Yam I, Friedman JM: Linkage of malignant hyperthermia and hyperkalemic periodic paralysis to the adult skeletal muscle sodium channel (SCN4A) gene in a large pedigree. Am J Med Genet 1998; 76:21-7
30. + channel inactivation by anemone toxin (ATX II) mimics the myotonic state in hyperkalaemic periodic paralysis. J Physiol 1993; 466:501-20
31. Larach MG: Standardization of the caffeine halothane muscle contracture test. Anesth Analg 1989; 69:511-5
32. European MH Group: Laboratory diagnosis of malignant hyperpyrexia susceptibility (MHS). Br J Anaesth 1985; 57:1038
33. Fletcher JE: Current laboratory methods for the diagnosis of malignant hyperthermia susceptibility, Anesthesiology Clinics of North America. Temperature Regulation During Anesthesia. Edited by Levitt RC. Philadelphia, WB Saunders, 1994, pp 553-70
34. Hartung E, Koob M, Anetseder M, Schoemig P, Krauspe R, Hogrefe G, Engelhardt W: Malignant hyperthermia (MH) diagnostics: A comparison between the halothane-caffeine and the ryanodine-contracture-test results in MH susceptible, normal and control muscle. Acta Anaesthesiol Scand 1996; 40:437-44
35. Wappler F, Roewer N, Lenzen C, Köchling A, Scholz J, Steinfath M, Schulte am Esch J: High-purity ryanodine and 9,21-dehydroryanodine for in vitro diagnosis of malignant hyperthermia in man. Br J Anaesth 1994; 72:240-2
36. Fletcher JE, Rosenberg H: In vitro interaction between halothane and succinylcholine in human skeletal muscle: Implications for malignant hyperthermia and masseter muscle rigidity. ANESTHESIOLOGY 1985; 63:190-4
37. Allen GC, Larach MG, Kunselman AR, The North American Malignant Hyperthermia Registry of MHAUS: The sensitivity and specificity of the caffeine-halothane contracture test. A report from the North American Malignant Hyperthermia Registry. ANESTHESIOLOGY 1998; 88:579-88
38. Stewart SL, Rosenberg H, Fletcher JE: Failure to identity the ryanodine receptor G1021A mutation in a large North American population with malignant hyperthermia. Clin Genet 1998; 54:358-60
39. Fletcher JE, Rosenberg H: In vitro muscle contractures induced by halothane and suxamethonium: I. The rat diaphragm. Br J Anaesth 1986; 58:1427-32
40. Sudbrak R, Procaccio V, Klausnitzer M, Curran JL, Monsieurs K, Van Broeckhoven C, Ellis R, Heyetens L, Hartung EJ, Kozak-Ribbens G, Heilinger D, Weissenbach J, Lehman-Horn F, Mueller CR, Deufel T, Stewart AD, Lunardi J: Mapping of a further malignant hyperthermia susceptibility locus to chromosome 3q13.1. Am J Human Genet 1995; 56:684-91
41. Cody JR: Muscle rigidity following administration of succinylcholine. ANESTHESIOLOGY 1968; 29:159-62
42. Erxleben C, Rathmayer W: Effects of the sea anemone Anemonia sulcata toxin II on skeletal muscle and on neuromuscular transmission. Toxicon 1984; 22:387-99
43. Adnet PJ, Krivosic-Horber RM, Haudecoeur G, Adamantidis MM, Reyford GH, Imbenotte M, Cordonnier C: Use of the calcium agonist BAY K 8644 for in vitro diagnosis of susceptibility to malignant hyperthermia. Br J Anaesth 1990; 65:791-5
44. Adnet PJ, Krivosic-Horber RM, Adamantidis MM, Reyford H, Cordonnier C, Haudecoeur G: Effects of calcium-free solution, calcium antagonists, and the calcium agonist BAY K 8644 on mechanical responses of skeletal muscle from patients susceptible to malignant hyperthermia. ANESTHESIOLOGY 1991; 75:413-9
45. Rosenberg H, Fletcher JE: International Malignant Hyperthermia Workshop and Symposium. Hiroshima, Japan, July 16-19, 1994. ANESTHESIOLOGY 1995; 82:803-5
46. 2+ and meat quality in young and adult halothane-sensitive and halothane-insensitive British Landrace pigs. Meat Sci 1986; 17:37-53
47. Fay RS, Gallant EM: Halothane sensitivity of young pigs in vivo and in vitro. Am J Physiol 1990; 259:R133-8
48. 2+-induced uncoupling and free fatty acids. Int J Biochem 1989; 21:913-20
49. Foster PS, Gesini E, Claudianos C, Hopkinson KC, Denborough MA: Inositol 1,4,5,-trisphosphate phosphatase deficiency and malignant hyperpyrexia in swine. Lancet 1989; i:124-6
50. 2+ channel/ryanodine receptor: Modulation by endogenous effectors, drugs and disease states. Pharmacol Rev 1997; 49:1-51
51. Ricker K, Moxley RT, Heine R, Lehmann-Horn F: Myotonia fluctuans. A third type of muscle sodium channel disease. Arch Neurol 1994; 51:1095-102